We recently compiled a list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts. Alnylam Pharmaceuticals, ...

Fintel reports that on July 21, 2025, Truist Securities initiated coverage of Alnylam Pharmaceuticals (NasdaqGS:ALNY) with a ...

Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) has been approved by the Medicines and Healthcare products Regulatory Agency ...

Some genetically targeted therapies are classified in the IRA as small-molecule drugs, limiting the incentive for biotech companies to pursue them, writes Alnylam CEO.

Insights from analysts' 12-month price targets are revealed, presenting an average target of $357.7, a high estimate of $404.00, and a low estimate of $325.00. Marking an increase of 10.61%, the ...

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he ...

Shares of Alnylam Pharmaceuticals (NASDAQ: ALNY) were sinking 9.5% lower as of 11:27 a.m. ET on Thursday after falling as much as 12.6% earlier in the day. The sell-off came after the drugmaker ...

Alnylam Pharma (ALNY) Company Description: Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics.

Buying $100 In ALNY: If an investor had bought $100 of ALNY stock 15 years ago, it would be worth $2,138.15 today based on a price of $325.64 for ALNY at the time of writing.

Present Market Standing of Alnylam Pharmaceuticals With a volume of 918,360, the price of ALNY is up 1.19% at $257.76. RSI indicators hint that the underlying stock may be overbought.

Ending one of two late-stage programs doesn't bode well for a 14-year-old biotech with nothing to sell yet. Alnylam was founded a little over 14 years ago. It doesn't have anything to sell yet ...

Canaccord Genuity analyst Whitney Ijem maintained a Buy rating on Alnylam Pharma (ALNY – Research Report) yesterday and set a price target of $366.00. Whitney Ijem has given his Buy rating due ...